Table 4

MTHFR C677T and breast cancer survival

Person-years1

# events2

HR (95% CI)3

p-value


C677T genotype (n = 198)

C/C

1

C/T or T/T

873

46

0.65 (0.31–1.35)

0.25

ER-negative (n = 84)

C/C

1

C/T or T/T

352

29

0.36 (0.12–1.04)

0.06

ER-positive (n = 114)

C/C

1

C/T or T/T

521

17

1.12 (0.35–3.59)

0.82

African-American (n = 121)

C/C

1

C/T or T/T

520

29

0.12 (0.02–0.92)

0.04

Caucasian (n = 77)

C/C

1

C/T or T/T

352

17

1.89 (0.57–6.32)

0.3

No Chemotherapy (n = 81)

C/C

1

C/T or T/T

394

13

0.88 (0.21–3.74)

0.87

Chemotherapy (n = 117)

C/C

1

C/T or T/T

479

33

0.55 (0.22–1.34)

0.19


1 Time at risk in person-years. 2 Number of deaths due to breast cancer. 3 Cox Proportional-Hazards regression with adjustments for age at diagnosis, race, A1298C, BMI, estrogen receptor, TNM stage, and chemotherapy.

Martin et al. BMC Cancer 2006 6:257   doi:10.1186/1471-2407-6-257

Open Data